IL17A and non-small cell lung carcinoma: In the HCC827 and PC9 EGFR-mutant NSCLC cell lines, we found that overexpression of IL-17A or treatment with rhIL-17A both enhanced EGFR activation, cell proliferation, and EGFR-TKI resistance.